Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 17 entries
Sorted by: Best Match Show Resources per page
Why and how to evaluate driving abilities in patients with neurodegenerative diseases?.

Geriatrie et psychologie neuropsychiatrie du vieillissement

Lazeras C, Cartier M, Bonnet M, Laurens B, Meissner WG, Planche V.
PMID: 34753708
Geriatr Psychol Neuropsychiatr Vieil. 2021 Nov 09; doi: 10.1684/pnv.2021.0975. Epub 2021 Nov 09.

Many studies have shown that individuals with neurodegenerative diseases are at risk of being involved in a traffic accident. However, driving is critical for social integration and independence in daily life. The lack of consensus and a standardised assessment...

Cite
Lazeras C, Cartier M, Bonnet M, et al. Why and how to evaluate driving abilities in patients with neurodegenerative diseases?. Geriatr Psychol Neuropsychiatr Vieil. 2021;doi: 10.1684/pnv.2021.0975.
Lazeras, C., Cartier, M., Bonnet, M., Laurens, B., Meissner, W. G., & Planche, V. (2021). Why and how to evaluate driving abilities in patients with neurodegenerative diseases?. Geriatrie et psychologie neuropsychiatrie du vieillissement, . https://doi.org/10.1684/pnv.2021.0975
Lazeras, Chloé, et al. "Why and how to evaluate driving abilities in patients with neurodegenerative diseases?." Geriatrie et psychologie neuropsychiatrie du vieillissement vol. (2021). doi: https://doi.org/10.1684/pnv.2021.0975
Lazeras C, Cartier M, Bonnet M, Laurens B, Meissner WG, Planche V. Why and how to evaluate driving abilities in patients with neurodegenerative diseases?. Geriatr Psychol Neuropsychiatr Vieil. 2021 Nov 09; doi: 10.1684/pnv.2021.0975. Epub 2021 Nov 09. PMID: 34753708.
Copy Download .nbib Format: NLM
Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study.

Joint bone spine

Ricard L, Laurent C, Papo M, Deriaz S, Catano J, Alamowitch S, Kayem G, Chasset F, De Moreuil C, Boffa JJ, Gerotziafas G, Elalamy I, Bornes M, Maillot F, Audemard-Verger A, Planche V, Ballot E, Fain O, Mekinian A.
PMID: 34656751
Joint Bone Spine. 2021 Oct 14;89(2):105297. doi: 10.1016/j.jbspin.2021.105297. Epub 2021 Oct 14.

INTRODUCTION: The antiphospholipid syndrome (APS) (1) is defined by the development of vascular thrombosis, or pregnancy morbidity in the presence of persistent antiphospholipid antibodies (aPL). Antinuclear antibodies (ANA) can be detected in primary APS patients without any clinical systemic...

Cite
Ricard L, Laurent C, Papo M, et al. Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study. Joint Bone Spine. 2021;89(2):105297doi: 10.1016/j.jbspin.2021.105297.
Ricard, L., Laurent, C., Papo, M., Deriaz, S., Catano, J., Alamowitch, S., Kayem, G., Chasset, F., De Moreuil, C., Boffa, J. J., Gerotziafas, G., Elalamy, I., Bornes, M., Maillot, F., Audemard-Verger, A., Planche, V., Ballot, E., Fain, O., & Mekinian, A. (2021). Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study. Joint bone spine, 89(2), 105297. https://doi.org/10.1016/j.jbspin.2021.105297
Ricard, Laure, et al. "Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study." Joint bone spine vol. 89,2 (2021): 105297. doi: https://doi.org/10.1016/j.jbspin.2021.105297
Ricard L, Laurent C, Papo M, Deriaz S, Catano J, Alamowitch S, Kayem G, Chasset F, De Moreuil C, Boffa JJ, Gerotziafas G, Elalamy I, Bornes M, Maillot F, Audemard-Verger A, Planche V, Ballot E, Fain O, Mekinian A. Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study. Joint Bone Spine. 2021 Oct 14;89(2):105297. doi: 10.1016/j.jbspin.2021.105297. Epub 2021 Oct 14. PMID: 34656751.
Copy Download .nbib Format: NLM
Distinct Hippocampal Subfields Atrophy in Older People With Vascular Brain Injuries.

Stroke

Pin G, Coupé P, Nadal L, Manjon JV, Helmer C, Amieva H, Mazoyer B, Dartigues JF, Catheline G, Planche V.
PMID: 33657856
Stroke. 2021 May;52(5):1741-1750. doi: 10.1161/STROKEAHA.120.031743. Epub 2021 Mar 04.

BACKGROUND AND PURPOSE: Many neurological or psychiatric diseases affect the hippocampus during aging. The study of hippocampal regional vulnerability may provide important insights into the pathophysiological mechanisms underlying these processes; however, little is known about the specific impact of...

Cite
Pin G, Coupé P, Nadal L, et al. Distinct Hippocampal Subfields Atrophy in Older People With Vascular Brain Injuries. Stroke. 2021;52(5):1741-1750doi: 10.1161/STROKEAHA.120.031743.
Pin, G., Coupé, P., Nadal, L., Manjon, J. V., Helmer, C., Amieva, H., Mazoyer, B., Dartigues, J. F., Catheline, G., & Planche, V. (2021). Distinct Hippocampal Subfields Atrophy in Older People With Vascular Brain Injuries. Stroke, 52(5), 1741-1750. https://doi.org/10.1161/STROKEAHA.120.031743
Pin, Grégoire, et al. "Distinct Hippocampal Subfields Atrophy in Older People With Vascular Brain Injuries." Stroke vol. 52,5 (2021): 1741-1750. doi: https://doi.org/10.1161/STROKEAHA.120.031743
Pin G, Coupé P, Nadal L, Manjon JV, Helmer C, Amieva H, Mazoyer B, Dartigues JF, Catheline G, Planche V. Distinct Hippocampal Subfields Atrophy in Older People With Vascular Brain Injuries. Stroke. 2021 May;52(5):1741-1750. doi: 10.1161/STROKEAHA.120.031743. Epub 2021 Mar 04. PMID: 33657856.
Copy Download .nbib Format: NLM
Differential Gray Matter Vulnerability in the 1 Year Following a Clinically Isolated Syndrome.

Frontiers in neurology

Koubiyr I, Deloire M, Coupé P, Dulau C, Besson P, Moroso A, Planche V, Tourdias T, Brochet B, Ruet A.
PMID: 30364223
Front Neurol. 2018 Oct 11;9:824. doi: 10.3389/fneur.2018.00824. eCollection 2018.

No abstract available.

Cite
Koubiyr I, Deloire M, Coupé P, et al. Differential Gray Matter Vulnerability in the 1 Year Following a Clinically Isolated Syndrome. Front Neurol. 2018;9:824doi: 10.3389/fneur.2018.00824.
Koubiyr, I., Deloire, M., Coupé, P., Dulau, C., Besson, P., Moroso, A., Planche, V., Tourdias, T., Brochet, B., & Ruet, A. (2018). Differential Gray Matter Vulnerability in the 1 Year Following a Clinically Isolated Syndrome. Frontiers in neurology, 9824. https://doi.org/10.3389/fneur.2018.00824
Koubiyr, Ismail, et al. "Differential Gray Matter Vulnerability in the 1 Year Following a Clinically Isolated Syndrome." Frontiers in neurology vol. 9 (2018): 824. doi: https://doi.org/10.3389/fneur.2018.00824
Koubiyr I, Deloire M, Coupé P, Dulau C, Besson P, Moroso A, Planche V, Tourdias T, Brochet B, Ruet A. Differential Gray Matter Vulnerability in the 1 Year Following a Clinically Isolated Syndrome. Front Neurol. 2018 Oct 11;9:824. doi: 10.3389/fneur.2018.00824. eCollection 2018. PMID: 30364223; PMCID: PMC6193084.
Copy Download .nbib Format: NLM
Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study.

Joint bone spine

Ricard L, Laurent C, Papo M, Deriaz S, Catano J, Alamowitch S, Kayem G, Chasset F, De Moreuil C, Boffa JJ, Gerotziafas G, Elalamy I, Bornes M, Maillot F, Audemard-Verger A, Planche V, Ballot E, Fain O, Mekinian A.
PMID: 34656751
Joint Bone Spine. 2021 Oct 14;89(2):105297. doi: 10.1016/j.jbspin.2021.105297. Epub 2021 Oct 14.

INTRODUCTION: The antiphospholipid syndrome (APS) (1) is defined by the development of vascular thrombosis, or pregnancy morbidity in the presence of persistent antiphospholipid antibodies (aPL). Antinuclear antibodies (ANA) can be detected in primary APS patients without any clinical systemic...

Cite
Ricard L, Laurent C, Papo M, et al. Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study. Joint Bone Spine. 2021;89(2):105297doi: 10.1016/j.jbspin.2021.105297.
Ricard, L., Laurent, C., Papo, M., Deriaz, S., Catano, J., Alamowitch, S., Kayem, G., Chasset, F., De Moreuil, C., Boffa, J. J., Gerotziafas, G., Elalamy, I., Bornes, M., Maillot, F., Audemard-Verger, A., Planche, V., Ballot, E., Fain, O., & Mekinian, A. (2021). Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study. Joint bone spine, 89(2), 105297. https://doi.org/10.1016/j.jbspin.2021.105297
Ricard, Laure, et al. "Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study." Joint bone spine vol. 89,2 (2021): 105297. doi: https://doi.org/10.1016/j.jbspin.2021.105297
Ricard L, Laurent C, Papo M, Deriaz S, Catano J, Alamowitch S, Kayem G, Chasset F, De Moreuil C, Boffa JJ, Gerotziafas G, Elalamy I, Bornes M, Maillot F, Audemard-Verger A, Planche V, Ballot E, Fain O, Mekinian A. Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study. Joint Bone Spine. 2021 Oct 14;89(2):105297. doi: 10.1016/j.jbspin.2021.105297. Epub 2021 Oct 14. PMID: 34656751.
Copy Download .nbib Format: NLM
US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?.

JAMA neurology

Planche V, Villain N.
PMID: 34515750
JAMA Neurol. 2021 Nov 01;78(11):1307-1308. doi: 10.1001/jamaneurol.2021.3126.

No abstract available.

Cite
Planche V, Villain N. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?. JAMA Neurol. 2021;78(11):1307-1308doi: 10.1001/jamaneurol.2021.3126.
Planche, V., & Villain, N. (2021). US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?. JAMA neurology, 78(11), 1307-1308. https://doi.org/10.1001/jamaneurol.2021.3126
Planche, Vincent, and Villain, Nicolas. "US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?." JAMA neurology vol. 78,11 (2021): 1307-1308. doi: https://doi.org/10.1001/jamaneurol.2021.3126
Planche V, Villain N. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?. JAMA Neurol. 2021 Nov 01;78(11):1307-1308. doi: 10.1001/jamaneurol.2021.3126. PMID: 34515750.
Copy Download .nbib Format: NLM
Lack of limbic-predominant age-related TDP-43 encephalopathy (LATE) neuropathological changes in aged macaques with memory impairment.

Neurobiology of aging

Darricau M, Canron MH, Bosc M, Arotçarena ML, Quang ML, Dehay B, Bezard E, Planche V.
PMID: 34384992
Neurobiol Aging. 2021 Nov;107:53-56. doi: 10.1016/j.neurobiolaging.2021.07.009. Epub 2021 Jul 21.

The neuropathological changes of limbic-predominant age-related TDP-43 encephalopathy (LATE) are frequent in the aged population and are now recognized as a cause of memory impairment. However, it remains unknown if this proteinopathy is also present in other primate species....

Cite
Darricau M, Canron MH, Bosc M, et al. Lack of limbic-predominant age-related TDP-43 encephalopathy (LATE) neuropathological changes in aged macaques with memory impairment. Neurobiol Aging. 2021;107:53-56doi: 10.1016/j.neurobiolaging.2021.07.009.
Darricau, M., Canron, M. H., Bosc, M., Arotçarena, M. L., Quang, M. L., Dehay, B., Bezard, E., & Planche, V. (2021). Lack of limbic-predominant age-related TDP-43 encephalopathy (LATE) neuropathological changes in aged macaques with memory impairment. Neurobiology of aging, 10753-56. https://doi.org/10.1016/j.neurobiolaging.2021.07.009
Darricau, Morgane, et al. "Lack of limbic-predominant age-related TDP-43 encephalopathy (LATE) neuropathological changes in aged macaques with memory impairment." Neurobiology of aging vol. 107 (2021): 53-56. doi: https://doi.org/10.1016/j.neurobiolaging.2021.07.009
Darricau M, Canron MH, Bosc M, Arotçarena ML, Quang ML, Dehay B, Bezard E, Planche V. Lack of limbic-predominant age-related TDP-43 encephalopathy (LATE) neuropathological changes in aged macaques with memory impairment. Neurobiol Aging. 2021 Nov;107:53-56. doi: 10.1016/j.neurobiolaging.2021.07.009. Epub 2021 Jul 21. PMID: 34384992.
Copy Download .nbib Format: NLM
Complement C3 mediates early hippocampal neurodegeneration and memory impairment in experimental multiple sclerosis.

Neurobiology of disease

Bourel J, Planche V, Dubourdieu N, Oliveira A, Séré A, Ducourneau EG, Tible M, Maitre M, Lesté-Lasserre T, Nadjar A, Desmedt A, Ciofi P, Oliet SH, Panatier A, Tourdias T.
PMID: 34673149
Neurobiol Dis. 2021 Dec;160:105533. doi: 10.1016/j.nbd.2021.105533. Epub 2021 Oct 19.

Memory impairment is one of the disabling manifestations of multiple sclerosis (MS) possibly present from the early stages of the disease and for which there is no specific treatment. Hippocampal synaptic dysfunction and dendritic loss, associated with microglial activation,...

Cite
Bourel J, Planche V, Dubourdieu N, et al. Complement C3 mediates early hippocampal neurodegeneration and memory impairment in experimental multiple sclerosis. Neurobiol Dis. 2021;160:105533doi: 10.1016/j.nbd.2021.105533.
Bourel, J., Planche, V., Dubourdieu, N., Oliveira, A., Séré, A., Ducourneau, E. G., Tible, M., Maitre, M., Lesté-Lasserre, T., Nadjar, A., Desmedt, A., Ciofi, P., Oliet, S. H., Panatier, A., & Tourdias, T. (2021). Complement C3 mediates early hippocampal neurodegeneration and memory impairment in experimental multiple sclerosis. Neurobiology of disease, 160105533. https://doi.org/10.1016/j.nbd.2021.105533
Bourel, Julien, et al. "Complement C3 mediates early hippocampal neurodegeneration and memory impairment in experimental multiple sclerosis." Neurobiology of disease vol. 160 (2021): 105533. doi: https://doi.org/10.1016/j.nbd.2021.105533
Bourel J, Planche V, Dubourdieu N, Oliveira A, Séré A, Ducourneau EG, Tible M, Maitre M, Lesté-Lasserre T, Nadjar A, Desmedt A, Ciofi P, Oliet SH, Panatier A, Tourdias T. Complement C3 mediates early hippocampal neurodegeneration and memory impairment in experimental multiple sclerosis. Neurobiol Dis. 2021 Dec;160:105533. doi: 10.1016/j.nbd.2021.105533. Epub 2021 Oct 19. PMID: 34673149.
Copy Download .nbib Format: NLM
Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study.

Joint bone spine

Ricard L, Laurent C, Papo M, Deriaz S, Catano J, Alamowitch S, Kayem G, Chasset F, De Moreuil C, Boffa JJ, Gerotziafas G, Elalamy I, Bornes M, Maillot F, Audemard-Verger A, Planche V, Ballot E, Fain O, Mekinian A.
PMID: 34656751
Joint Bone Spine. 2021 Oct 14;89(2):105297. doi: 10.1016/j.jbspin.2021.105297. Epub 2021 Oct 14.

INTRODUCTION: The antiphospholipid syndrome (APS) (1) is defined by the development of vascular thrombosis, or pregnancy morbidity in the presence of persistent antiphospholipid antibodies (aPL). Antinuclear antibodies (ANA) can be detected in primary APS patients without any clinical systemic...

Cite
Ricard L, Laurent C, Papo M, et al. Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study. Joint Bone Spine. 2021;89(2):105297doi: 10.1016/j.jbspin.2021.105297.
Ricard, L., Laurent, C., Papo, M., Deriaz, S., Catano, J., Alamowitch, S., Kayem, G., Chasset, F., De Moreuil, C., Boffa, J. J., Gerotziafas, G., Elalamy, I., Bornes, M., Maillot, F., Audemard-Verger, A., Planche, V., Ballot, E., Fain, O., & Mekinian, A. (2021). Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study. Joint bone spine, 89(2), 105297. https://doi.org/10.1016/j.jbspin.2021.105297
Ricard, Laure, et al. "Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study." Joint bone spine vol. 89,2 (2021): 105297. doi: https://doi.org/10.1016/j.jbspin.2021.105297
Ricard L, Laurent C, Papo M, Deriaz S, Catano J, Alamowitch S, Kayem G, Chasset F, De Moreuil C, Boffa JJ, Gerotziafas G, Elalamy I, Bornes M, Maillot F, Audemard-Verger A, Planche V, Ballot E, Fain O, Mekinian A. Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study. Joint Bone Spine. 2021 Oct 14;89(2):105297. doi: 10.1016/j.jbspin.2021.105297. Epub 2021 Oct 14. PMID: 34656751.
Copy Download .nbib Format: NLM
Pilot Study Assessing the Impact of Intrathecal Administration of Variants AAV-PHP.B and AAV-PHP.eB on Brain Transduction in Adult Rhesus Macaques.

Frontiers in bioengineering and biotechnology

Arotcarena ML, Dovero S, Biendon N, Dutheil N, Planche V, Bezard E, Dehay B.
PMID: 34869273
Front Bioeng Biotechnol. 2021 Nov 15;9:762209. doi: 10.3389/fbioe.2021.762209. eCollection 2021.

Adeno-associated virus (AAV) vectors are increasingly used as an effective and safe approach to deliver genetic material to the central nervous system (CNS). The AAV9-derived variants, AAV-PHP. B and AAV-PHP.eB, reportedly broadly transduce cells throughout the CNS compared to...

Cite
Arotcarena ML, Dovero S, Biendon N, et al. Pilot Study Assessing the Impact of Intrathecal Administration of Variants AAV-PHP.B and AAV-PHP.eB on Brain Transduction in Adult Rhesus Macaques. Front Bioeng Biotechnol. 2021;9:762209doi: 10.3389/fbioe.2021.762209.
Arotcarena, M. L., Dovero, S., Biendon, N., Dutheil, N., Planche, V., Bezard, E., & Dehay, B. (2021). Pilot Study Assessing the Impact of Intrathecal Administration of Variants AAV-PHP.B and AAV-PHP.eB on Brain Transduction in Adult Rhesus Macaques. Frontiers in bioengineering and biotechnology, 9762209. https://doi.org/10.3389/fbioe.2021.762209
Arotcarena, Marie-Laure, et al. "Pilot Study Assessing the Impact of Intrathecal Administration of Variants AAV-PHP.B and AAV-PHP.eB on Brain Transduction in Adult Rhesus Macaques." Frontiers in bioengineering and biotechnology vol. 9 (2021): 762209. doi: https://doi.org/10.3389/fbioe.2021.762209
Arotcarena ML, Dovero S, Biendon N, Dutheil N, Planche V, Bezard E, Dehay B. Pilot Study Assessing the Impact of Intrathecal Administration of Variants AAV-PHP.B and AAV-PHP.eB on Brain Transduction in Adult Rhesus Macaques. Front Bioeng Biotechnol. 2021 Nov 15;9:762209. doi: 10.3389/fbioe.2021.762209. eCollection 2021. PMID: 34869273; PMCID: PMC8634843.
Copy Download .nbib Format: NLM
Lack of limbic-predominant age-related TDP-43 encephalopathy (LATE) neuropathological changes in aged macaques with memory impairment.

Neurobiology of aging

Darricau M, Canron MH, Bosc M, Arotçarena ML, Quang ML, Dehay B, Bezard E, Planche V.
PMID: 34384992
Neurobiol Aging. 2021 Nov;107:53-56. doi: 10.1016/j.neurobiolaging.2021.07.009. Epub 2021 Jul 21.

The neuropathological changes of limbic-predominant age-related TDP-43 encephalopathy (LATE) are frequent in the aged population and are now recognized as a cause of memory impairment. However, it remains unknown if this proteinopathy is also present in other primate species....

Cite
Darricau M, Canron MH, Bosc M, et al. Lack of limbic-predominant age-related TDP-43 encephalopathy (LATE) neuropathological changes in aged macaques with memory impairment. Neurobiol Aging. 2021;107:53-56doi: 10.1016/j.neurobiolaging.2021.07.009.
Darricau, M., Canron, M. H., Bosc, M., Arotçarena, M. L., Quang, M. L., Dehay, B., Bezard, E., & Planche, V. (2021). Lack of limbic-predominant age-related TDP-43 encephalopathy (LATE) neuropathological changes in aged macaques with memory impairment. Neurobiology of aging, 10753-56. https://doi.org/10.1016/j.neurobiolaging.2021.07.009
Darricau, Morgane, et al. "Lack of limbic-predominant age-related TDP-43 encephalopathy (LATE) neuropathological changes in aged macaques with memory impairment." Neurobiology of aging vol. 107 (2021): 53-56. doi: https://doi.org/10.1016/j.neurobiolaging.2021.07.009
Darricau M, Canron MH, Bosc M, Arotçarena ML, Quang ML, Dehay B, Bezard E, Planche V. Lack of limbic-predominant age-related TDP-43 encephalopathy (LATE) neuropathological changes in aged macaques with memory impairment. Neurobiol Aging. 2021 Nov;107:53-56. doi: 10.1016/j.neurobiolaging.2021.07.009. Epub 2021 Jul 21. PMID: 34384992.
Copy Download .nbib Format: NLM
Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study.

Joint bone spine

Ricard L, Laurent C, Papo M, Deriaz S, Catano J, Alamowitch S, Kayem G, Chasset F, De Moreuil C, Boffa JJ, Gerotziafas G, Elalamy I, Bornes M, Maillot F, Audemard-Verger A, Planche V, Ballot E, Fain O, Mekinian A.
PMID: 34656751
Joint Bone Spine. 2021 Oct 14;89(2):105297. doi: 10.1016/j.jbspin.2021.105297. Epub 2021 Oct 14.

INTRODUCTION: The antiphospholipid syndrome (APS) (1) is defined by the development of vascular thrombosis, or pregnancy morbidity in the presence of persistent antiphospholipid antibodies (aPL). Antinuclear antibodies (ANA) can be detected in primary APS patients without any clinical systemic...

Cite
Ricard L, Laurent C, Papo M, et al. Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study. Joint Bone Spine. 2021;89(2):105297doi: 10.1016/j.jbspin.2021.105297.
Ricard, L., Laurent, C., Papo, M., Deriaz, S., Catano, J., Alamowitch, S., Kayem, G., Chasset, F., De Moreuil, C., Boffa, J. J., Gerotziafas, G., Elalamy, I., Bornes, M., Maillot, F., Audemard-Verger, A., Planche, V., Ballot, E., Fain, O., & Mekinian, A. (2021). Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study. Joint bone spine, 89(2), 105297. https://doi.org/10.1016/j.jbspin.2021.105297
Ricard, Laure, et al. "Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study." Joint bone spine vol. 89,2 (2021): 105297. doi: https://doi.org/10.1016/j.jbspin.2021.105297
Ricard L, Laurent C, Papo M, Deriaz S, Catano J, Alamowitch S, Kayem G, Chasset F, De Moreuil C, Boffa JJ, Gerotziafas G, Elalamy I, Bornes M, Maillot F, Audemard-Verger A, Planche V, Ballot E, Fain O, Mekinian A. Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study. Joint Bone Spine. 2021 Oct 14;89(2):105297. doi: 10.1016/j.jbspin.2021.105297. Epub 2021 Oct 14. PMID: 34656751.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 17 entries